United States, Nov. 10 -- Evonik has manufactured the first batch of GMP-quality pharmaceutical lipids at its new Lipid Innovation Center (LINC) in Lafayette, Indiana, USA. Supported by the U.S. government, the large-scale facility at Evonik's Tippecanoe site will produce pharmaceutical lipids that enable the manufacture of advanced therapies in the U.S. Full capacity is scheduled to come on stream by mid-2027. LINC is a flexible production center designed to support multiple lipid chemistries, manufacturing processes and products. These therapies are used in areas such as cancer immunotherapy, gene therapy, and vaccine platforms that support preparedness for future infectious disease outbreaks. Lipids are essential for encapsulating and de...